<?xml version="1.0" encoding="UTF-8"?>
<p>Fingolimod is mainly contra-indicated in patients with myocardial infarction (within six months), unstable angina, stroke, heart failure, and heart block. Prolonged QT interval above 500 m/s is another important contra-indication, given the high incidence of myocarditis as a complication of severe COVID-19. Patients with diabetes may get macular edema upon fingolimod treatment [
 <xref rid="B100-pharmaceuticals-13-00096" ref-type="bibr">100</xref>]. A clinical trial has been registered to use fingolimod at a dose of 0.5 mg daily for three consecutive days in the treatment of severe COVID-19 infection (NCT04280588).
</p>
